AVANIR Pharmaceuticals (AVNR)
A pharmaceutical company focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.
Recs
PicoTrader
(< 20)
Submitted: 9/1/2009 3:13:05 PM :
Start Price:
$1.88
AVNR Score:
-16.95
pharma play.
Recs
sempire
(39.31)
Submitted: 8/11/2009 3:16:17 PM :
Start Price:
$2.82
AVNR Score:
-48.88
Looking good so far as the FDA is concerned, and continued R&D will prove to be valuable for this stock. Looking for interest from the big boys.
Recs
Recs
bahlmann
(< 20)
Submitted: 7/13/2009 10:55:25 AM :
Start Price:
$1.88
AVNR Score:
-30.48
A history of large swings
Recs
jss6439
(28.72)
Submitted: 7/3/2007 5:16:01 PM :
Start Price:
$2.69
AVNR Score:
+11.00
I just sold this stock knowing it is going to underperform.If your'e a player it has its moments but catch on the downside.
Recs
trevormccoy
(< 20)
Submitted: 6/2/2007 12:29:03 PM :
Start Price:
$3.29
AVNR Score:
-22.56
Follow up Phase III data coming soon.
Recs
praslee
(21.16)
Submitted: 5/29/2007 6:54:55 PM :
Start Price:
$3.02
AVNR Score:
+18.86
There is no near sight of anything big. The stock is already doubled since the last news. So it is time to cool off.
Recs
AGAPE1646
(< 20)
Submitted: 5/11/2007 1:26:42 AM :
Start Price:
$2.73
AVNR Score:
-13.62
AVNR has reached the bottom of its price range as a result of the 'approvable' FDA letter for Zenvia.
AVNR is making the right moves by downsizing R&D and conserving cash to fund the 2nd round PhIII clinical it will need to perform.
Zenvia has two good (and nearly unique) neurological indications - involuntary emotional expression disorder and diabetic neuropathy.
AVNR will need to raise cash (sell assets) or sell the company, so a good buyout premium is likely. This is most suitable as a short term investment.
Recs
entropy2
(< 20)
Submitted: 5/6/2007 10:43:46 PM :
Start Price:
$3.38
AVNR Score:
-25.30
Pure speculation stock - but better odds than the lottery.
Recs
Recs
NuvoRiche
(64.31)
Submitted: 4/19/2007 8:24:40 PM :
Start Price:
$4.28
AVNR Score:
+37.50
Zenvia - dextromethorphan/quinidine. Hocus-pocus. Old meds, no new technology here. Meds have potentially concerning side effects for diabetics, I just don't see blockbuster potential even if approved.
Recs
dabears54
(92.75)
Submitted: 4/18/2007 2:21:30 PM :
Start Price:
$4.90
AVNR Score:
-43.16
Clinical trial showed Zenvia significantly lessened chronic nerve pain in diabetic patients! The company is planning to meet with the FDA to discuss the next stage of clinical studies. Personally knowing someone with chronic pain due to diabeties, Zenvia will have a significant impact on his life and the countless others suffering from the similar symptoms.
Very promising long term investment!!!
Recs
mpfd33
(68.13)
Submitted: 11/4/2006 10:12:57 PM :
Start Price:
$7.25
AVNR Score:
-66.12
Obviously highly speculative. It ain't over till the fat lady sings. Some think she's warming up her throat. At this point...and in my real portfolio, there is not much to lose by hanging on. Let's see what the FDA says first. Good luck to all, we will need it with this play.
Recs
bsoile6
(< 20)
Submitted: 11/3/2006 10:41:00 AM :
Start Price:
$3.00
AVNR Score:
-26.72
over maybe 30 to 35%
Recs
StockXtrader
(22.93)
Submitted: 11/1/2006 1:00:57 PM :
Start Price:
$3.58
AVNR Score:
-35.78
Oversold on News! Drug gets approved! Stock goes much higher!
Recs
cramersaprentice
(49.36)
Submitted: 10/31/2006 8:54:28 PM :
Start Price:
$3.95
AVNR Score:
-40.09
After todays whollop on this stock and so many downgrades this is now a buy
Recs
Malstryx
(99.02)
Submitted: 10/31/2006 11:18:54 AM :
Start Price:
$4.16
AVNR Score:
-42.50
I think this was oversold, short term play.
Recs
bluegreene
(70.77)
Submitted: 10/16/2006 8:36:12 AM :
Start Price:
$8.66
AVNR Score:
-65.10
Great potential
Recs
camor
(25.71)
Submitted: 10/14/2006 3:42:18 PM :
Start Price:
$8.66
AVNR Score:
-65.10
Waiting for FDA to approve new drug dealing with controlling emotional outbursts.
Recs
vicker50
(< 20)
Submitted: 9/13/2006 8:13:16 PM :
Start Price:
$6.47
AVNR Score:
-61.49
october 31st they should be approved for nuerodex (1 year behind schedule). they hold world wide marketing/distribution rights to this drug.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 21 1 2 Next »